Prescribing information and Adverse event reporting can be found at the bottom of the page
Brand Navigation Banner
Search Header
What is endometrial hyperplasia?
Endometrial hyperplasia is broadly defined as an excessive cellular proliferation leading to an increased volume of endometrial tissue. It is characterised by an increase in the endometrial gland-to-stroma ratio greater than 1:1.1
Endometrial hyperplasia is further classified as simple or complex, with or without atypia. This classification system is based on the complexity and crowding of the glandular architecture.1
The most common presenting symptom of endometrial hyperplasia is abnormal uterine bleeding, including:
However, endometrial hyperplasia can also be asymptomatic and can spontaneously regress without being detected.1
- Palmer JE, et al. Obstet Gynecol 2008;10211-216 Return to content
- RCOG/BSGE Management of Endometrial Hyperplasia [online] February 2016. Available from https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf. Last accessed: May 2022. Return to content
Histological classification of endometrial hyperplasia
Normal endometrium
Endometrial hyperplasia
Adapted from Palmer JE, et al. Obstet Gynecol 2008; 10:211-216.
Hisological classification: Proliferative endometrium
- Glands are tubular and regularly spaced in Glanstroma
- Glands are lined with pseudostratified nuclei
- Mitotic figures are easily found in glands and stroma
Adapted from Palmer JE, et al. Obstet Gynecol 2008; 10:211-216.
Hisological classification: Simple hyperplasia
- Irregular glands varying in size and shape, set in abundant stroma
- Cystic glands present
- Glandular cells show nuclear pseudostratification
- No nuclear atypia
Adapted from Palmer JE, et al. Obstet Gynecol 2008; 10:211-216.
Hisological classification: Complex hyperplasia
- Glands are closely packed
- Stroma is relatively sparse
- Nuclei are uniform, oval and psuedostratified
- Nucleoli are indistinct
Adapted from Palmer JE, et al. Obstet Gynecol 2008; 10:211-216.
Hisological classification: Complex atypical hyperplasia
- Glands irregular and tightly packed
- Lack of stroma
- Nuclei are large and vesicular
- Prominent nucleoli
Adapted from Palmer JE, et al. Obstet Gynecol 2008; 10:211-216.
Aetiology and risk factors
Oestrogen stimulates endometrial proliferation.1 A relative excess of oestrogen (exogenous or endogenous) compared with progesterone is considered to be one of the principle causes in endometrial hyperplasias.1
Key risk factors in post-menopausal women include:
Other risk factors include:
- Palmer JE, et al. Obstet Gynecol 2008;10211-216. Return to content
- Fu YS, et al. West J Med 1990;15350-61. Return to content
- Sanderson PA, et al. Hum Reprod Update 2017;23:232-254. Return to content
Incidence and diagnosis
- RCOG/BSGE Management of Endometrial Hyperplasie [online] February 2016. Available from https://www.rcog.org.uk/globalassets/documents/guidelines/green-top-guidelines/gtg_67_endometrial_hyperplasia.pdf. Last accessed May 2022. Return to content
- Chandra V, et al. J Gynecol Oncol 2016:27:eB. Return to content
The only levonorgestrel intrauterine system licensed for four years for endometrial protection during oestrogen replacement therapy (ERT)1
Efficacy and safety profile
The efficacy of Mirena® in preventing oestrogen-induced hyperplasia in peri-menopausal and postmenopausal women has been assessed in various studies.2,3
Mirena® significantly decreased menstrual bleeding compared with conventional oral hormone replacement therapy (P=0.001, N=200).2
Continuing Mirena® use during the transition from contraception to ERT has no known additional adverse events on the vaginal bleeding profile.5
The proportion of patients who had difficulties in coping with any items from the Women's Health Questionnaire decreased over time, during both the contraception and ERT phases with Mirena®.5
- FSRH. Intrauterine Contraception [online] April 2015. Amended September 2019. Available from: https://www.fsrh.org/standards-and-guidance/documents/ceuguidanceintrauterinecontraception/. Last accessed May 2022. Return to content
- Boon J, et al. Maturitas 2003;46:69-77. Return to content
- Chandra V, et al. J Gynecol Oncol. 201627e8. Return to content
- Raudaskoski T, et al. BJOG 2002;109 136-144. Return to content
- Depypere H, et al. Eur J Obst Gyn Repr Biol 2010;153:176-18O. Return to content
Latest content
PP-PF-WHC-GB-1035 May 2022
Reporting adverse events and quality complaints
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Bayer plc.
If you want to report an adverse event or quality complaint, reports can be directed to: Tel: 01182063500 or email: pvuk@bayer.com
Further information is available on the “contact” tab at www.bayer.co.uk.
